All In Biotech

Drug Trial Radar · NCT05695781

Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.

A Multi-Center, Randomized, Double Masked, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of BRM421 Ophthalmic Solution in Subjects With Dry Eye Using a Controlled Adverse Environment (CAE®) Model

Last checked: Nov 19, 2026Latest source record: Jul 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 740 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

740

Actual

Start

Feb 27, 2023

Primary completion

Dec 30, 2023

Study completion Mar 30, 2024

Sponsor

Lead sponsor
BRIM Biotechnology Inc.Industry
Sponsor type
Industry
First posted
Jan 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to compare the safety and efficacy of BRM421 OS to vehicle for the treatment of the signs and symptoms of dry eye disease.

Conditions

  • Dry Eye Disease

Interventions

  • BRM421 Ophthalmic SolutionDrug

    A topical drop of BRM421 ophthalmic solution.

  • VehicleDrug

    A topical drop of vehicle (minus active) ophthalmic solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular Sign: Change From Baseline in Total Corneal Fluorescein Staining ScoreTime frame: 1-2 weeks
  2. Ocular Symptom: Change From Baseline in Visual Analog Scale (VAS)Time frame: 1-2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Andover Eye Associates

    Warwick, Rhode Island

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.